Patients with cancer are heterogeneous concerning the risk for VTE. Some solid
malignancies including pancreatic, lung, colon-rectum, ovarian, and brain cancer are …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer …

The Khorana score is recommended for guiding primary venous thromboembolism (VTE)
prophylaxis in cancer patients, but its clinical utility overall and across cancer types remains …

Background Cancer patients receiving chemotherapy are at increased risk of thrombosis.
Nadroparin has been demonstrated to reduce the incidence of venous and arterial …

Cancer patients are at increased risk of developing venous thromboembolism (VTE).
Guidelines recommend routine thromboprophylaxis in hospitalised acutely ill cancer …

Background Oncology guidelines suggest using the Khorana score to select ambulatory
cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) …

Risk of venous thromboembolism (VTE) is elevated in cancer, but individual risk factors
cannot identify a sufficiently high-risk group of outpatients for thromboprophylaxis. We …

Background The stratification of outpatients on chemotherapy for breast, colorectal, lung,
and ovarian cancers at risk of venous thromboembolism (VTE) remains an unmet clinical …

Introduction. The occurrence of malignant disease increases the risk for venous
thromboembolism (VTE). Here we evaluate the risk for VTE in a large unselected cohort of …

We aimed to evaluate the performance of the Khorana score in predicting venous
thromboembolic events in ambulatory cancer patients. Embase and MEDLINE were …